Montag, 14. Juni 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 
JOURNAL ONKOLOGIE – STUDIE

Post Market Clinical Follow-up Study Venezia

Rekrutierend

NCT-Nummer:
NCT03958357

Studienbeginn:
April 2019

Letztes Update:
04.03.2021

Wirkstoff:
-

Indikation (Clinical Trials):
Uterine Cervical Neoplasms

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Nucletron Operations BV

Collaborator:
Factory CRO

Studienleiter

Ina Jurgenliemk-Schulz, MD, PhD
Principal Investigator
UMC Utrecht
Alina Sturdza, MD
Principal Investigator
Medical University Vienna
Robert Hobbs, MD
Principal Investigator
Johns Hopkins University
Elizabeth Harris, MD
Principal Investigator
University Hospital Case Western
Stefanie Corradini, Dr. med.
Principal Investigator
Ludwig-Maximilians - University of Munich
Ina Jurgenliemk-Schulz, MD, PhD
Study Chair
UMC Utrecht
Christian Kirisits, Prof. Dr.
Study Chair
Medical University Vienna

Kontakt

Studienlocations
(3 von 3)

University Medical Centre Utrecht
3584 CX Utrecht
NetherlandsRekrutierend» Google-Maps
Ansprechpartner:
Ina Jürgenliemk-Schulz, MD, PhD
Phone: +31 (0)88 755 8800 / +31 (0)88
E-Mail: radiotherapie@umcutrecht.nl
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

This is a multi-center, prospective, post-market clinical follow-up study to assess the

performance and the unknown risks or complications of the Advanced Gynecological Applicator

(AGA) Venezia configuration during clinical use of the applicator. The AGA Venezia

configuration is a CE-marked, FDA approved and commercially available product. The AGA

Venezia configuration is a gynaecological applicator for intracavitary and interstitial

brachytherapy. The radiation oncologist can use it for treatment of cancers in the vagina,

cervix and uterus. Forty (40) participants will be included in this study at 5 sites: 3

centers in Europe and 2 centers in the United States.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Patients with locally advanced cervical cancer stage IB to IVA

- Patients eligible for brachytherapy according to the criteria of the treating

radiation oncologist and center guidelines

- Patients that are eligible to undergo brachytherapy with the Advanced Gynecological

Applicator Venezia Configuration according to the criteria of the treating radiation

oncologist

- Patient is able to understand and has voluntarily signed and dated the Ethics

Committee approved informed consent form prior to initiation of any screening or

study-specific procedures.

Exclusion Criteria:

- Patients that have been treated or will be treated for cancer other than cervical

cancer.

- Advanced stage cervical cancer patients who have been treated with pelvic

radiotherapy, incl. brachytherapy, before.

- Patients younger than 18 years at the time of diagnosis.

Studien-Rationale

Primary outcome:

1. Performance of the AGA Venezia configuration applicator as assessed by the 'Applicator Performance Questionnaire' (Time Frame - Within one week after each individual insertion. No change is assessed. The procedure is performed per hospital standard. On average, the procedure and applicator insertions are performed twice.):
Performance of the device is assessed via the 'Applicator Performance Questionnaire' completed by the radiation oncologist. Scale is as follows: Completely Agree/Agree/Neutral/Disagree/Completely Disagree/Not Applicable. The primary endpoint, the third question ('I am able to deliver conformal dose to the tumor target volume while effectively avoiding the organs at risk') on the Questionnaire will be summarized through descriptive statistics in general summary tables. Additionally, responses will be recoded numerically ('Completely agree' = 1, 'Agree' = 2, 'Neutral' = 3, 'Disagree' = 4, and 'Completely disagree' = 5). A five-number summary (min, first quartile, median, third quartile and max) and a boxplot will be shown. The question will also be recoded as success ('Completely agree'&'Agree') and failure ('Neutral', 'Disagree' & 'Completely disagree').



Secondary outcome:

1. Risks and/or complications of the AGA Venezia configuration applicator as assessed by the 'Risks and Complications Questionnaire' (Time Frame - Immediately after each insertion and followed up during the first follow-up visit, typically three months after the last insertion. The procedure is performed per hospital standard. On average, the procedure and applicator insertions are performed twice.):
Unknown risks or complications are assessed via the 'Risks and Complications Questionnaire' completed by the treating radiation oncologist. The treating radiation oncologist will be asked to complete this questionnaires to assess whether risks and complications occurred or not. There is no scale, but answer options include yes/no. The value "NO" is considered a better outcome. "YES" constitutes the worst outcome. Descriptive statistics presented in general summary tables will be provided, summarizing the number of non-missing observations (n), mean, standard deviation, minimum, median and maximum for quantitative data. For categorical data, frequency counts and percentages will be determined.

Geprüfte Regime

  • Advanced Gynecological Applicator configuration:
    The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Aktionswoche zur Aufklärung über Kopf-Hals-Krebs
Aktionswoche+zur+Aufkl%C3%A4rung+%C3%BCber+Kopf-Hals-Krebs
© Merck Serono

Merck, ein führendes Wissenschafts- und Technologieunternehmen, hat heute bekannt gegeben, dass es sich auch in diesem Jahr an der Aktionswoche zu Kopf-Hals-Krebs beteiligt. Diese wird zum vierten Mal von der Europäischen Kopf-Hals-Gesellschaft (engl.: European Head and Neck Society, EHNS) initiiert und findet vom 19. bis 23. September 2016 statt. Im Rahmen der europaweiten Aktivitäten veranstalten mehrere deutsche Kliniken und...

Frauenärzte der GenoGyn fordern Maßnahmen gegen riskanten Alkoholkonsum
Frauen%C3%A4rzte+der+GenoGyn+fordern+Ma%C3%9Fnahmen+gegen+riskanten+Alkoholkonsum
© karepa / Fotolia.com

Beim Alkoholkonsum belegt Deutschland im weltweiten Vergleich stets Spitzenplätze: Rund zehn Liter reinen Alkohols werden hierzulande nach aktuellen Informationen des Bundesgesundheitsministeriums jedes Jahr pro Kopf getrunken und verursachen alljährlich volkswirtschaftliche Schäden in Höhe von 26,7 Milliarden Euro. „Obwohl Erkenntnisse über das Suchtpotenzial von Alkohol in der Gesellschaft inzwischen...